FuturHealth vs Midi Health
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
FuturHealth
Best for readers who want both brand-name and compounded GLP-1 options on one platform with registered-dietitian nutrition coaching, AND are willing to read the data-breach litigation disclosure before signing upStarting at $199/mo
Midi Health
Best for women in menopause / perimenopause with commercial insurance who want GLP-1 prescribing as part of a broader hormone + metabolic care plan, not as a standalone weight-loss productStarting at $128/mo
Side-by-Side Comparison
| Feature | FuturHealth | Midi Health |
|---|---|---|
| Overall Score | 6.7/10 | ✓7.0/10 |
| Starting Price | $199/mo | ✓$128/mo |
| Editorial Rating | 3.4 ★ /5 | ✓3.5 ★ /5 |
| Features | ✓8 features | 4 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
FuturHealth
Pros
- ✓LegitScript Certified and HITRUST Certified — two independently verifiable telehealth/health-data trust marks
- ✓Both brand-name (Ozempic, Wegovy, Mounjaro, Zepbound) and clinician-discretionary compounded options on one platform
- ✓Bundled registered-dietitian nutrition guidance — most pure-Rx telehealths leave nutrition support to the patient
Cons
- ✗ACTIVE LITIGATION: Wilson v. FuturHealth Inc., U.S. District Court Southern District of California, Case No. 3:2025cv00157, alleging unauthorized access to G-Plans subscriber data on/before October 16, 2024 and asserting CCPA, medical-confidentiality, and negligence claims. Material disclosure for any reader signing up.
- ✗BBB complaint pattern: multiple consumer reports of recurring unauthorized charges (e.g. $396/month) without medication being received — verify cancellation flow before subscribing
- ✗Pharmacy partners are described as 'licensed, U.S.-based pharmacies' but no specific 503A/503B partners are publicly named
- ✗Pricing is not displayed on the public landing page — visible only after qualification questionnaire/portal login
- ✗Clinical platform is white-labeled on top of SteadyMD and OpenLoop infrastructure — FuturHealth is the front-end brand, not the first-party prescribing entity
Midi Health
Pros
- ✓Nationwide availability in all 50 states (verified on the public homepage)
- ✓Accepts commercial insurance — differentiator vs most cash-pay-only GLP-1 telehealth
- ✓Menopause + metabolic health specialty framing — useful for women in the demographic where GLP-1 efficacy and weight regulation overlap most
- ✓Compounded semaglutide pricing starts at $127.90/mo for uninsured patients per the public pricing/insurance page
Cons
- ✗Does NOT accept Medicare, Medicaid, or Medi-Cal — eliminates roughly 40% of the insured US adult population
- ✗GLP-1 prescribing is clinician-discretionary inside a broader menopause care plan, NOT a guaranteed offering at intake — readers signing up purely for GLP-1 access may not get it
- ✗Menopause-focused — not the right fit for men or younger women whose primary need is weight loss
Our Verdict
Midi Health edges out FuturHealth with a higher overall score of 7.0/10 and is particularly strong for women in menopause / perimenopause with commercial insurance who want GLP-1 prescribing as part of a broader hormone + metabolic care plan, not as a standalone weight-loss product. FuturHealth remains a solid alternative, especially if you're looking for readers who want both brand-name and compounded GLP-1 options on one platform with registered-dietitian nutrition coaching, AND are willing to read the data-breach litigation disclosure before signing up.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.